MindMed’s MM120 Receives Breakthrough Therapy Designation for Anxiety Treatment

In a significant leap forward for mental health, Mind Medicine (MindMed) Inc. has announced that its proprietary LSD-based drug, MM120, has been granted breakthrough therapy designation by the U.S. Food & Drug Administration (FDA) specifically for the treatment of generalized anxiety disorder (GAD). The Science Behind MM120 MM120, also known as Lysergide d-tartrate, represents a novel approach to anxiety treatment. Unlike traditional pharmaceuticals, MM120 […]

MindMed’s MM120 Receives Breakthrough Therapy Designation for Anxiety Treatment Read More »